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Impaired β-glucocerebrosidase activity and
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to progranulin mutations
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Charles F. Murchison1,3, Eliana Marisa Ramos4, Alissa L. Nana5, Salvatore Spina5, Lea T. Grinberg5,6, Bruce L. Miller5,
William W. Seeley5,6 and Erik D. Roberson1,7*
Abstract
Loss-of-function mutations in progranulin (GRN) are a major autosomal dominant cause of frontotemporal
dementia. Most pathogenic GRN mutations result in progranulin haploinsufficiency, which is thought to cause
frontotemporal dementia in GRN mutation carriers. Progranulin haploinsufficiency may drive frontotemporal
dementia pathogenesis by disrupting lysosomal function, as patients with GRN mutations on both alleles develop
the lysosomal storage disorder neuronal ceroid lipofuscinosis, and frontotemporal dementia patients with GRN
mutations (FTD-GRN) also accumulate lipofuscin. The specific lysosomal deficits caused by progranulin insufficiency
remain unclear, but emerging data indicate that progranulin insufficiency may impair lysosomal sphingolipid-
metabolizing enzymes. We investigated the effects of progranulin insufficiency on sphingolipid-metabolizing
enzymes in the inferior frontal gyrus of FTD-GRN patients using fluorogenic activity assays, biochemical profiling of
enzyme levels and posttranslational modifications, and quantitative neuropathology. Of the enzymes studied, only
β-glucocerebrosidase exhibited impairment in FTD-GRN patients. Brains from FTD-GRN patients had lower activity
than controls, which was associated with lower levels of mature β-glucocerebrosidase protein and accumulation of
insoluble, incompletely glycosylated β-glucocerebrosidase. Immunostaining revealed loss of neuronal β-
glucocerebrosidase in FTD-GRN patients. To investigate the effects of progranulin insufficiency on β-
glucocerebrosidase outside of the context of neurodegeneration, we investigated β-glucocerebrosidase activity in
progranulin-insufficient mice. Brains from Grn−/− mice had lower β-glucocerebrosidase activity than wild-type
littermates, which was corrected by AAV-progranulin gene therapy. These data show that progranulin insufficiency
impairs β-glucocerebrosidase activity in the brain. This effect is strongest in neurons and may be caused by
impaired β-glucocerebrosidase processing.
Keywords: Progranulin, Lysosome, β-Glucocerebrosidase, Glycosphingolipid, Frontotemporal dementia, Neuronal
Ceroid Lipofuscinosis
Introduction
Loss-of-function mutations in progranulin (GRN) are an
autosomal dominant cause of frontotemporal dementia
(FTD), causing as much as 5–10% of FTD cases [5, 16, 20].
Most of these mutations cause progranulin
haploinsufficiency, with GRN carriers having less than half
of normal circulating progranulin levels [19]. In rare cases,
individuals have been found with loss-of-function GRN
mutations on both alleles, resulting in an almost complete
loss of progranulin [2, 59]. Instead of FTD, these individuals
develop a lysosomal storage disorder, neuronal ceroid lipo-
fuscinosis (NCL), characterized by neurodegeneration and
accumulation of lysosomal storage material [2, 59]. Brains
from FTD-GRN patients accumulate similar storage mater-
ial as NCL patients [25, 67], so lysosomal dysfunction may
be a key mechanism of FTD-GRN pathogenesis.
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Understanding how the lysosome is impaired by pro-
granulin insufficiency may enable targeted therapies for
FTD due to GRN mutations. Emerging data indicate that
progranulin may regulate activity of lysosomal enzymes
involved in sphingolipid metabolism. Progranulin inter-
acts with and facilitates lysosomal localization of prosa-
posin [45, 73, 74], a pro-protein which is cleaved into
saposin fragments that serve as critical co-factors for
sphingolipid-metabolizing enzymes [57, 58]. Progranulin
insufficiency disrupts prosaposin trafficking in the brain
[74]. In some cell types, progranulin regulates trafficking
and activity of at least two enzymes involved in sphingo-
lipid metabolism, β-hexosaminidase A (HexA) [14] and
β-glucocerebrosidase (GCase) [29, 30]. We therefore hy-
pothesized that progranulin insufficiency would impair
activity of sphingolipid-metabolizing enzymes in the
brain. To test this hypothesis, we measured enzyme
activity, levels, and post-translational modifications in
inferior frontal gyrus of FTD-GRN patients and frontal
cortex of progranulin-insufficient mice. We assessed the
interaction of progranulin with GCase in cultured cells
and investigated the effects of AAV-progranulin gene
therapy on GCase enzyme activity in Grn−/− mice.
Materials and methods
Patient brain samples
Post-mortem brain samples were provided by the Neu-
rodegenerative Disease Brain Bank at the University of
California, San Francisco. Brains were donated with the
consent of the patients or their surrogates in accordance
with the Declaration of Helsinki, and the research was
approved by the University of California, San Francisco
Committee on Human Research. Tissue blocks were dis-
sected from the inferior frontal gyrus of 5 controls and 7
patients with FTD-GRN. All patients with FTD-GRN car-
ried a pathogenic variant in GRN and had FTLD-TDP,
Type A identified at autopsy, except one (case 7) discussed
more extensively in the text. More extensive patient charac-
teristics are provided in Table 1. Clinical and neuropatho-
logical diagnoses were made using standard diagnostic
criteria [23, 35, 36, 43, 53]. GBA sequencing data were
available for a subset of patients. These samples were
screened by targeted sequencing of a panel of genes impli-
cated in neurodegenerative disorders [52]. Coding and
exon-intron boundary regions of the GBA gene were
screened for pathogenic variants classified according to the
American College of Medical Genetics and Genomics and
the Association for Molecular Pathology guidelines [54]. All
patients with available data (1 control and 4 FTD-GRN
patients) were negative for pathogenic GBA variants.
Animals
Grn−/− mice were generated and crossed onto a C57BL/6 J
background as previously described [18, 37]. Wild-type,
Grn+/−, and Grn−/− mice for this study were generated by
crossing male and female Grn+/− mice. The resulting
littermates were used for all mouse studies, and both male
and female littermates were used. The mice were housed
in a barrier facility accredited by the Association for As-
sessment and Accreditation of Laboratory Animal Care,
under conditions previously described [4]. All experiments
were approved by the Institutional Animal Care and Use
Committee of the University of Alabama at Birmingham.
Fibroblasts
Fibroblast lines were purchased from the NIGMS Human
Genetic Cell Repository at the Coriell Institute for Medical
Research. We analyzed cells from an apparently healthy line
(#GM00730), a heterozygous GBA L444P line (#GM00878),
and two homozygous GBA L444P lines (#GM08760 and
GM00877). Fibroblasts were cultured in MEM (Corning Life
Sciences) with 15% fetal bovine serum (Atlanta Biologicals)
and 1% penicillin/streptomycin (ThermoFisher) at 37 °C and
5% CO2. Deglycosylation reactions were carried out on
25 μg of protein as described below.
Tissue preparation
For initial western blot and lysosomal activity assays, tis-
sue from mouse frontal cortex or human inferior frontal
gyrus was homogenized in lysis buffer (50 mM Tris, 150
mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% sodium
deoxycholate) and spun at 5000 x g for 10 min. Protein
content of the supernatant was measured by Bradford
assay, and equal amounts of total protein from each
sample were used for subsequent assays.
Western blot
Samples were run on 4–12% bis-tris polyacrylamide gels
(ThermoFisher), transferred to Immobilon-FL PVDF
(MilliporeSigma), and probed overnight with primary anti-
body. The following primary antibodies were used: rabbit
polyclonal GCase (#G4171, MilliporeSigma), mouse mono-
clonal GCase (#sc-166,407, Santa Cruz Biotechnology),
cathepsin D (goat polyclonal, #sc-6486, Santa Cruz Bio-
technology), LAMP-1 (mouse monoclonal, #sc-20,011,
Santa Cruz Biotechnology), LAMP-2 (mouse monoclonal,
#sc-18,822, Santa Cruz Biotechnology), GAPDH (mouse
monoclonal, #MAB374, MilliporeSigma), Flag (mouse
monoclonal, #F3165, MilliporeSigma), and progranulin
(rabbit polyclonal, #40–3400, ThermoFisher). Blots were
then probed with species-matched IRdye-conjugated sec-
ondary antibodies (Li-COR Biosciences) and scanned on
an Odyssey scanner (Li-COR Biosciences).
Lysosomal activity assays
Activity of β-galactosidase (β-Gal), β-hexosaminidase
(total) (Hex), β-hexosaminidase A (HexA), α-galactosidase
A (GLA), and β-glucocerebrosidase (GCase) was
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determined in tissue lysates by incubation with fluoro-
genic substrates at 37 °C. All reactions resulted in produc-
tion of the fluorophore 4-methylumbelliferone (4-MU),
and were read on a Synergy 2 plate reader (Biotek Instru-
ments) with a 360 nm excitation wavelength and a 440 nm
emission wavelength. Data were quantitated relative to
a standard curve of 4-MU run on each plate and cal-
culated as nmol 4-MU generated per hour per mg of
protein loaded. For all reactions, a uniform amount of
protein was loaded per well, ranging from 5 to 20 μg
depending on the assay.
Activity of Hex and HexA was determined by incubation
with 2mM substrate (for β-Hex - 4-methylumbelliferyl-2-
acetamido-2-deoxy-β-D-glucopyranoside, MilliporeSigma,
for HexA - 4-methylumbelliferyl-2-acetamido-2-deoxy-6-
sulfate-β-D-glucopyranoside, Research Products Inter-
national) in 10mM sodium citrate buffer, pH 4.2 [69]. Re-
actions were stopped with 0.2M glycine, 0.2M sodium
carbonate.
Activity assays for GCase (substrate: 1 mM 4-
Methylumbelliferyl β-D-glucopyranoside, Millipore-
Sigma), GLA (substrate: 4.3 mM 4-Methylumbelliferyl
α-D-galactopyranoside, MilliporeSigma) and β-Gal (sub-
strate: 1 mM 4-Methylumbelliferyl β-D-galactopyranoside,
MilliporeSigma) were conducted in pH 4.6 citrate phos-
phate buffer and stopped with 0.4M glycine, pH 10.8. For
GCase, the reaction buffer included 1% bovine serum
albumin, 0.25% triton X-100, 0.25% taurocholic acid, and
1mM EDTA [44]. Specific GCase activity was confirmed
by correcting for fluorescence generated in the presence
of a GCase inhibitor, 0.18mM conduritol β-epoxide (Enzo
Life Sciences). Specific GLA activity was determined by
inhibition of non-specific substrate cleavage by α-
galactosidase B using 90mMN-acetyl-D-galactosamine
(MilliporeSigma) [44].
Endoglycosidase H and PNGase F treatment
Tissue lysates prepared as described above were incu-
bated with endoglycosidase H (New England Biolabs) or
PNGase F (New England Biolabs) according to the man-
ufacturer’s instructions as previously described [3]. For
each sample, a control tube was run for each enzyme
that contained all reaction components except for the
enzyme. Reactions containing 50 μg of protein were
incubated overnight at 37 °C, then processed for western
blot as described above.
Sarkosyl soluble/insoluble fractionation
Sarkosyl soluble and insoluble fractions were prepared
using a previously described protocol [17]. Protein con-
tent of the fractions was determined by BCA assay
(ThermoFisher), and equivalent amounts of protein from
each sample were processed for western blot as de-
scribed above.
Immunostaining
Formalin-fixed blocks of inferior frontal gyrus were pro-
vided by the Neurodegenerative Disease Brain Bank at
the University of California, San Francisco. Tissue blocks
were cryoprotected in 30% sucrose and cut into 30 μm
sections on a sliding microtome. Prior to immunostaining,
sections underwent antigen retrieval in 10mM sodium
citrate, pH 6.0 at 80 °C for 2 h. Sections were then washed
in PBS and immunostained as previously described using
rabbit polyclonal (#G4171, MilliporeSigma) or mouse
monoclonal anti-GCase antibodies (#MAB7410, R&D Sys-
tems) [50]. Sections were blocked in 10% normal goat
serum, 1% milk, and 0.2% gelatin prior to overnight incu-
bation with primary antibody diluted in 3% normal goat
serum and 0.2% gelatin. After washing, sections were
probed with species-matched secondary antibodies diluted
in 3% normal goat serum and 0.2% gelatin. Sections were
then washed and incubated with avidin-biotin complex
(VectaStain Elite, Vector Laboratories). Immunostaining
was detected by incubating with 3,3′-diaminobenzidene
(MP Biomedicals) in 100mM Tris, pH 7.4. All antibody
incubations and washes were conducted with PBS con-
taining 0.5% Triton X-100. Initial quantification of GCase
immunolabeling was performed on sections with no coun-
terstain, but in follow-up studies sections were counter-
stained with either Cresyl violet (MilliporeSigma) or
hematoxylin (Fisher Scientific). For fluorescent immu-
nostaining, sections were co-stained with a rabbit
monoclonal anti-NeuN antibody (#ab177487, Abcam).
GCase immunolabeling was detected with an AlexaFluor-
488 anti-mouse antibody (ThermoFisher Scientific), and
NeuN immunolabeling was detected with an AlexaFluor-
594 anti-rabbit antibody (ThermoFisher Scientific).
Fluorescently-labeled sections were stained with 1% Sudan
Black (Acros Organics) to quench autofluorescence.
Imaging and analysis
Imaging and analysis of GCase-immunostained tissue
was performed by investigators blinded to experimental
group. Chromogenic GCase-immunostained tissue sec-
tions were imaged at 20X on a brightfield microscope
(Nikon) and analyzed using ImageJ. For each patient, 2–
3 20X fields of view were captured in cortical layer III.
Total GCase immunoreactivity was assessed on sections
with no counterstain by measuring the area falling
within a uniform intensity threshold. In a follow-up
study, sections were counterstained with hematoxylin.
Hematoxylin (blue) and GCase (brown) labeling were
deconvoluted, and neurons were defined by using
ImageJ’s Analyze Particles feature to draw ROIs. These
ROIs were then overlaid onto the GCase image to define
neuronal GCase immunoreactivity.
Fluorescently-stained sections were imaged at 40X on
a Nikon A1R confocal. For each patient 2–4 z-stacks of
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25 μm thickness were obtained using 0.5 μm z-steps.
Maximum intensity projections were made of both
NeuN and GCase immunoreactivity. Neuronal ROIs
were drawn using ImageJ’s analyze particles feature on
the NeuN images. These ROIs were overlaid onto the
GCase images to measure the fluorescent intensity of
each neuron.
Cell culture and co-immunoprecipitation
HEK-293 cells (#CRL-1573, ATCC) were cultured in
DMEM (Corning Life Sciences) with 10% fetal bovine
serum (Atlanta Biologicals), and 1% penicillin/streptomycin
(ThermoFisher) at 37 °C and 5% CO2. Cells were transiently
transfected with a plasmid expressing human GBA1 with a
C-terminal myc-flag tag (#RC216061, Origene), and/or a
construct expressing human progranulin with an N-
terminal HA tag inserted after the signal peptide in the pre-
viously described CIGW vector [4, 60]. After 48 h, the cells
were harvested in lysis buffer (50mM Tris, 150mM NaCl,
5mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate)
and centrifuged 10min at 5000 x g. HA-tagged progranulin
was immunoprecipitated from 100 μg of lysate protein
using 2.5 μg of anti-HA tag antibody (mouse monoclonal,
#sc-7392, Santa Cruz Biotechnology) as described above.
Immunoprecipitates were blotted for Flag tag (mouse
monoclonal, #F3165, MilliporeSigma) to detect co-
immunoprecipitated GCase, and for progranulin to
confirm successful pull down of HA-tagged progranu-
lin (rabbit polyclonal, #40–3400, ThermoFisher).
Proximity ligation assays
HEK-293 cells were cultured on 12 mm No. 1 glass
coverslips (Carolina Biological) coated with 0.1 mg/mL
Poly-D-Lysine (MilliporeSigma) and 0.02 mg/mL lam-
inin (MilliporeSigma), then transfected with GBA-
myc-Flag and HA-GRN plasmids as described above.
Forty-eight hours after transfection, cells were fixed
in 4% paraformaldehyde and 4% sucrose. The cover-
slips were incubated overnight at 4 °C with anti-HA
(rabbit monoclonal, #3274, Cell Signaling Technolo-
gies) and anti-Flag (goat polyclonal, #ab1257, Abcam)
antibodies, and probed the next day with a Duolink
proximity ligation kit (MilliporeSigma) with donkey
anti-rabbit and donkey anti-goat probes using the
manufacturer’s protocol. All coverslips were imaged
with an epifluorescent microscope (Nikon) at 60x.
Lipidomics
Levels of glucosylceramide isoforms and glucosylsphin-
gosine were measured at the Lipidomics Shared Re-
source at the Medical University of South Carolina.
Shavings from frozen tissue blocks were homogenized
(lysate buffer: 0.25M sucrose, 25 mM KCl, 0.5 mM
EDTA, 50mM Tris, pH 7.4), and protein content was
determined by Bradford assay. Lipids were extracted
from lysate containing 1 mg of total protein, and were
measured with high-performance liquid chromatog-
raphy/mass spectrometry as previously described [8].
AAV administration
The effects of AAV-progranulin on GCase activity in
Grn−/− mice were measured in ventral striatum samples
from mice used in a previous study of AAV-progranulin
[4]. A second group of mice was injected with AAV-
progranulin or AAV-GFP by infusion in the medial pre-
frontal cortex as previously described [4]. These mice
were treated at 3–6 months of age and euthanized for
tissue collection 4 weeks later.
Experimental design & statistics
Lysosomal enzyme activity, protein levels, and chromogenic
immunostaining in patient samples were analyzed by t-test.
The intensity of fluorescent GCase immunolabeling was
analyzed by mixed-effects regression models with random
effects intercept term blocking on subjects to account for
the repeated measures. Linear mixed-models were used to
compare mean intensities between groups while quantile
regression was used to compare deciles. Levels of glucosyl-
ceramide isoforms were analyzed by MANOVA. Lysosomal
enzyme activity in mice was analyzed by one-way ANOVA.
Main effects of genotype were followed by Dunnett’s post-
hoc test to compare Grn+/− and Grn−/− mice to wild-type.
The effects of AAV-progranulin in ventral striatum samples
were analyzed by two-way ANOVA with factors of geno-
type and virus. The effects of AAV-progranulin across mul-
tiple brain regions were analyzed by repeated-measures
ANOVA with factors of genotype, virus, and brain region,
followed by individual repeated measures ANOVA for each
genotype with factors of virus and brain region. These two-
way repeated measures ANOVA were followed by Sidak’s
post-hoc test to analyze the effect of virus within each brain
region. MANOVA and three-way repeated measures
ANOVA were performed with SPSS 24 (IBM), Mixed-
model regression was performed with R with additional
utility from the lme4 and lqmm packages, and all other
analyses were performed with Graphpad Prism 7 (Graph-
Pad). For all analyses, two-tailed p values were calculated,
with α set at 0.05.
Results
Increased HexA and decreased GCase activity patients
with FTD-GRN
We hypothesized that progranulin insufficiency would im-
pair the activity of sphingolipid-metabolizing enzymes in
the brain. To test this hypothesis, we measured activity of
β-galactosidase (β-Gal), total β-hexosaminidase (β-Hex),
β-hexosaminidase A (HexA), α-galactosidase A (GLA),
and β-glucocerebrosidase (GCase) in postmortem samples
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of inferior frontal gyrus from controls and patients with
FTD-GRN (Fig. 1a). We detected an increase in HexA ac-
tivity (Fig. 1d) and a reduction in GCase activity (Fig. 1f),
but no change in β-Gal, GLA, or total β-Hex activity in
FTD-GRN patients relative to controls.
This pattern of changes in enzyme activity was not
consistent with a generalized impairment of saposin-
dependent enzymes [58], as β-Gal and GLA require
saposin B for optimal activity but were unchanged in
FTD-GRN patients. Instead, the selective changes in
HexA and GCase activity in FTD-GRN patients may be
related to their reported interaction with progranulin
[14, 29, 30]. The opposite directionality of the changes
in HexA and GCase was somewhat surprising. Progranu-
lin may facilitate the processing and lysosomal traffick-
ing of both enzymes, which could result in reduced
activity under progranulin-insufficient conditions [14,
29, 30]. However, we and others have observed increased
HexA activity in brains from progranulin-insufficient
mice [3, 33, 61, 62], perhaps indicating cell-type–specific
effects of progranulin-insufficiency on enzyme function.
To gain further insight into the mechanisms underlying
the altered HexA and GCase activity, we investigated
how the changes in enzyme activity related to enzyme
levels in brains of FTD-GRN patients.
Increased HexA protein levels in patients with FTD-GRN
We observed elevated HexA protein levels in FTD-GRN
patients relative to controls (Additional file 1: Figure S1a).
This increase in HexA levels is consistent with a general
increase in lysosomal proteins in FTD-GRN patients [25]
and progranulin-insufficient mice [24, 25, 33, 61, 62].
Consistent with these prior reports, we also observed
elevated LAMP-1 and LAMP-2 levels, and a trend for in-
creased mature cathepsin D levels in FTD-GRN patients
(Additional file 1: Figure S1). Given the general increase in
lysosomal proteins in FTD-GRN patients, the increase in
HexA and other lysosomal proteins may be a compensa-
tory response to lysosomal dysfunction caused by progra-
nulin haploinsufficiency.
Abnormal GCase processing in FTD-GRN
We next assessed GCase protein levels by immunoblot
with two GCase antibodies, both of which revealed lower
levels of mature GCase protein in patients with FTD-
GRN than controls (Fig. 2a–c). This reduction in GCase
differed distinctly from the potentially compensatory
increases in HexA and other lysosomal proteins in the
same samples. Immunoblots with a rabbit polyclonal
anti-GCase antibody revealed an abnormal lower mo-
lecular weight band (Fig. 2a) in all but one of the pa-
tients with FTD-GRN (the exception being case #7 in
Table 1, which was unique as further discussed below).
We hypothesized that this band might be composed of
incompletely glycosylated GCase, indicative of abnormal
GCase processing. Under this hypothesis, the opposite
directionality of GCase relative to other lysosomal pro-
teins would be due to impairment of GCase processing
that prevents a compensatory increase in GCase, such as
we have previously observed in Grn+/− mice [3].
To test this hypothesis, we treated tissue lysates with
the deglycosylating enzymes Peptide-N-glycosidase F
Fig. 1 Deficits in GCase Activity in Inferior Frontal Gyrus from Patients with FTD-GRN. Lysates from inferior frontal gyrus of controls and FTD-GRN
patients were analyzed for activity of sphingolipid-metabolizing enzymes. a, Simplified diagram of metabolism of gangliosides, with a summary of
observed phenotypes in FTD-GRN cases. Lipids are shown in black, with the enzymes that metabolize each lipid shown in blue. GM1, 2, and 3 = GM1,
2, and 3 ganglioside, β-Gal = β-galactosidase, β-Hex = β-Hexosaminidase, HexA = β-Hexosaminidase A, GLA = α-galactosidase A, GCase = β-
glucocerebrosidase, Neu = neuraminidase (activity not measured in this study). b–f, Enzymatic activity in FTD-GRN patient brains as measured by
fluorogenic assays for b, β-Gal, c, β-Hex, d, HexA, which was increased (* = t test, p = 0.0474), e, GLA, and f, GCase, which was decreased (** = t test,
p = 0.0015). n = 5 controls, 7 FTD-GRN
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(PNGase F) or Endoglycosidase H (Endo H) and immu-
noblotted the reaction products with the polyclonal
GCase antibody (Fig. 2d). PNGase F removes most N-
linked glycans from glycosylated proteins, resulting in a
shift to lower molecular weight in SDS-PAGE. With
PNGase F treatment, both the normal- and lower mo-
lecular weight GCase bands shifted to a single band just
above 50 kDa, confirming that the lower molecular
weight band in FTD-GRN patients was composed of in-
completely glycosylated GCase. There were no group
differences in the density of the completely deglycosyl-
ated GCase band (Fig. 2e), showing that brains from
FTD-GRN patients contain a similar amount of total
GCase protein as controls, but less fully glycosylated,
active GCase (Figs. 1f and 2a–c).
In contrast to PNGase F, Endo H is only capable of
removing immature glycans that have not undergone
final processing in the Golgi apparatus. Thus, in-
creased Endo H-sensitivity is an indicator that a pro-
tein may have been misfolded and retained in the
endoplasmic reticulum. Neither the normal or lower
molecular weight GCase bands were fully Endo H-
sensitive in FTD-GRN samples (Fig. 2d, defined as shifting
to the completely deglycosylated band), though Endo H
treatment produced a small shift in the mature GCase band
in all samples, including controls. The lower molecular
Fig. 2 Lower Levels of Mature GCase Protein and Accumulation of Incompletely Glycosylated GCase in Brains from FTD-GRN Patients. a–c, Lysates
of inferior frontal gyrus from FTD-GRN cases had lower levels of normal molecular-weight GCase protein than controls as detected by a rabbit
polyclonal anti-GCase antibody (b, t test, p = 0.0059), and a mouse monoclonal anti-GCase antibody (c, t test, p = 0.0017). The polyclonal antibody
also detected a lower molecular weight band that was present in all but one FTD-GRN case, but rarely in controls. d, To determine whether this
lower molecular weight band could represent incompletely glycosylated GCase, lysates were treated with Endo H or PNGase F. The lower-
molecular weight GCase band (red arrowhead) was approximately the same molecular weight as Endo H-treated GCase. Complete removal of
glycosylation with PNGase F collapsed the multiple GCase bands into one band just over 50 kDa, indicating that the low-molecular weight form
of GCase detected by the polyclonal antibody may consist of incompletely glycosylated GCase. The higher molecular weight band detected by
the mouse monoclonal antibody was determined to be non-specific because it did not shift with PNGase F treatment (data not shown). e, Unlike
normal molecular weight GCase, there were no group differences in deglycosylated (PNGase F-treated) GCase (t test, p = 0.9594), showing that
while FTD-GRN brains contain less normal molecular weight, active GCase than controls, they have similar total levels of GCase protein. f, The
low-molecular weight form of GCase accumulated in the sarkosyl-insoluble fraction of FTD-GRN brains, while normal molecular weight GCase was
only detectable in the soluble fractions. Levels of sarkosyl-insoluble GCase did not statistically differ between controls and FTD-GRN patients
(g, Mann-Whitney test, p = 0.1490), but the insoluble band was detectable in 6/7 FTD-GRN patients, but only reliably detectable in 1/5 controls.
This stands in contrast to α-tubulin (f, h), which did not differ between groups. Levels of insoluble GCase were very high in some FTD-GRN
patients, so data in g are shown in log scale. n = 5 controls, and 7 FTD-GRN. * = p < 0.05 and ** = p < 0.1 by Tukey’s post-hoc test. GCase = β-
glucocerebrosidase, Endo = Endoglycosidase H, PNG = PNGase F
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weight GCase band seen in FTD-GRN (red arrowhead in
Fig. 2d) was roughly the same size as Endo H–treated
GCase, consistent with an incomplete glycosylation pattern.
Taken together, the PNGase F and Endo H data indi-
cate that impaired GCase activity in FTD-GRN pa-
tients is due to abnormal GCase processing with
incomplete glycosylation.
As a positive control for these experiments, we ana-
lyzed GCase immunoblots from fibroblasts carrying the
L444P mutation in GBA (the gene encoding GCase)
which causes the lysosomal storage disorder Gaucher
disease in homozygous carriers [27]. The GBA L444P
mutation produces misfolded GCase that is retained in
the endoplasmic reticulum and is incompletely glycosyl-
ated [7]. We observed nearly complete loss of mature,
glycosylated GCase in homozygous L444P fibroblasts
and accumulation of lower molecular weight, incom-
pletely glycosylated GCase in heterozygous and homozy-
gous L444P fibroblasts (Additional file 2: Figure S2),
thus confirming that the polyclonal GCase antibody can
detect both fully and incompletely processed GCase.
To further investigate abnormal GCase processing, we
measured GCase in the soluble and insoluble fractions
of brains from controls and FTD-GRN patients using a
standard sarkosyl-soluble/insoluble fractionation proto-
col [17] (Fig. 2f–h). We detected normal molecular
weight GCase primarily in the sarkosyl-soluble fraction.
However, the lower molecular weight, incompletely gly-
cosylated form of GCase was enriched in the sarkosyl-
insoluble fraction of 6 of the 7 FTD-GRN brains, indicat-
ing accumulation of insoluble, immature GCase. In con-
trast, only one of the control patients accumulated
readily detectable amounts of insoluble GCase (Fig. 2g,
Additional file 3: Figure S3a).
A unique GRN carrier without a clinical or pathological
FTD spectrum diagnosis
Only one of the seven patients with a GRN mutation
completely lacked the abnormal low-molecular weight
GCase band (Additional file 3: Figure S3a). This patient
also had the least severe deficits in GCase activity and
protein levels, which were within the normal range
(Additional file 3: Figure S3b–d). Interestingly, this case
(#7 in Table 1) was also clinically and pathologically
unique. It was the only GRN case without a primary
clinical diagnosis of FTD, having features most consist-
ent with dementia with Lewy bodies (DLB). Consistent
with that clinical diagnosis, this patient had a primary
neuropathological diagnosis of diffuse neocortical Lewy
body disease, with only the beginnings of FTLD-TDP
type A pathology (Table 1, Additional file 3: Figure S3e).
This patient thus represents a rare case of a GRN carrier
coming to autopsy before FTD symptoms or robust
FTLD-TDP pathology manifested, having died from
DLB. While this is a single case, it is notable that the
only FTD-GRN patient in which GCase processing defi-
cits were absent also had the mildest TDP-43 pathology.
Loss of neuronal GCase in FTD-GRN
We next conducted GCase immunostaining to assess
which cell types are affected by the loss of GCase in
FTD-GRN patients. We immunostained sections of
inferior frontal gyrus with the rabbit polyclonal GCase
antibody used in the preceding experiments, as well as a
second mouse monoclonal GCase antibody. In a prelim-
inary study with L444P Gaucher fibroblasts, we con-
firmed that the rabbit polyclonal antibody detected both
mature, fully glycosylated and immature, incompletely
glycosylated GCase, but the mouse monoclonal antibody
selectively detected mature, fully glycosylated GCase, not
recognizing the lower molecular weight band (Fig. 3a).
Immunostaining of control sections revealed similar pat-
terns of immunolabeling with each antibody (Fig. 3b, d),
with particularly strong labeling of layer III pyramidal
neurons. We therefore measured GCase immunolabeling
in 20X images of layer III. Consistent with western blot
data (Fig. 2d), FTD-GRN patients did not have a signifi-
cant reduction in total GCase immunolabeling with the
rabbit polyclonal antibody (Fig. 3b, c). In contrast, the
mouse monoclonal antibody selective for mature GCase
revealed a clear reduction in mature.
GCase immunolabeling (Fig. 3d, e). With both antibodies,
there appeared to be a loss of strongly GCase-
immunolabeled layer III pyramidal neurons, which is con-
sistent with layer III neuronal loss in FTD. We therefore
performed additional experiments to determine if the GCase
deficits in FTD-GRN patients were driven by neuronal loss.
To determine if the loss of neuronal GCase in FTD-
GRN patients was simply a consequence of neuronal
loss, we employed two approaches to assess GCase in
surviving neurons of FTD-GRN patients. First, we used
hematoxylin counterstaining to identify pyramidal neu-
rons in sections stained for mature GCase with the
mouse monoclonal antibody (Fig. 4a). As expected,
FTD-GRN patients had fewer hematoxylin-labeled neu-
rons than controls, resulting in a lower total neuronal
area (Fig. 4b). ROIs were drawn around hematoxylin-
labeled neurons to measure neuronal GCase immunola-
beling, revealing that FTD-GRN patients had less neur-
onal GCase immunolabeling than controls (Fig. 4c). This
reduced neuronal GCase immunolabeling survived cor-
rection for the reduced neuronal area of FTD-GRN
patients (Fig. 4d). This indicates that while neuronal loss
likely contributes to some loss of GCase activity in FTD-
GRN patients, the surviving neurons still have less
GCase immunolabeling than controls.
Second, we assessed neuronal GCase immunolabeling
with fluorescent microscopy. Neurons were identified by
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NeuN immunoreactivity, which labeled both the nucleus
(strongly) and soma (faintly) of pyramidal neurons (Fig. 4e)
[40]. We measured the mean intensity of GCase immunola-
beling in ROIs drawn around NeuN-positive neurons and
obtained measurements from 80 to 147 neurons per patient
from 5 controls and 11–132 neurons per patient from 6
FTD-GRN patients. Initial analyses of these data revealed
lower GCase immunolabeling in FTD-GRN patients than
controls, both by comparing the average intensity of all
neurons measured (t test, p < 0.001) and by comparing the
distribution of GCase intensity between neurons from
controls and FTD-GRN patients (Fig. 4f, g, Kolmogorov-
Smirnov test, p < 0.0001). We then conducted a follow-up
analysis to determine if this difference was driven by true
group differences, instead of by the greater number of
neurons detected in controls or by variability in the neu-
rons from specific patients. This subsequent analysis was
performed with a mixed-model regression to account for
serial correlation within subjects, then with undersampling
as a sensitivity assessment to limit the influence of any
one patient. This mixed-model analysis confirmed signifi-
cant distribution-based differences in fluorescent intensity
between groups, with the control distribution being sig-
nificantly skewed toward higher intensity relative to FTD-
GRN patients (Fig. 4f, g). Undersampling with a limit of
no more than 40 neurons per patient yielded similar
results with no change in statistical significance (Add-
itional file 4: Figure S4). These data show that FTD-
GRN patients have less neuronal GCase than controls,
and that this decrease cannot be explained entirely by
neuronal loss, but is also caused by a reduction in
the amount of mature GCase per neuron.
FTD-GRN patients do not accumulate GCase substrates
Given the loss of GCase activity in the brain, we tested
whether FTD-GRN patients accumulated the GCase sub-
strates glucosylceramide (GlcCer) and glucosylsphingosine
Fig. 3 Lower GCase Immunolabeling in FTD-GRN. We performed GCase immunostaining with the rabbit polyclonal antibody used in the
preceding biochemical experiments and a second mouse monoclonal antibody. a, using homozygous GBA L444P fibroblasts, we confirmed that
the rabbit polyclonal antibody detected an immature form of GCase (also see Additional file 2: Figure S2), but the mouse monoclonal antibody
was selective for mature, fully glycosylated GCase. We analyzed GCase immunolabeling in each group in layer III, which contained many strongly-
labeled pyramidal neurons in controls. b, c, FTD-GRN patients did not exhibit significantly less GCase immunolabeling with the rabbit polyclonal
antibody (t test, p = 0.2042). d, e, In contrast, FTD-GRN patients had significantly less GCase immunolabeling with the mouse monoclonal
antibody selective for mature GCase (t test, p = 0.0285). Low power images of GCase immunoreactivity throughout the cortex are shown in b and
d, with 100 μm scale bars, with representative 20x images of GCase immunostaining below with a 20 μm scale bars. The numbers for each image
reference the patients described in Table 1
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(GlcSph), which accumulate in the brain of patients with
neuronopathic Gaucher disease due to severe GCase defi-
ciency [46, 49]. We did not observe accumulation of any
GlcCer isoforms (Fig. 5a), total GlcCer (Fig. 5b), or GlcSph
(Fig. 5c) in FTD-GRN patients. This is consistent with
data from heterozygous GBA mutation carriers [9, 22],
and indicates that the remaining GCase activity is suffi-
cient to prevent accumulation of these lipids.
Progranulin and GCase interact
Progranulin has recently been reported to interact with
GCase and facilitate proper GCase processing and traffick-
ing to the lysosome [29, 30]. Our findings are consistent
with these data, so we next sought to confirm that progra-
nulin interacts with GCase. We co-transfected HEK-293
cells with constructs expressing HA-tagged human
progranulin (HA-GRN) and/or myc-Flag-tagged hu-
man GCase (GBA-myc-Flag), and immunoprecipitated
human progranulin from lysates of these cells with an
HA-tag antibody. Consistent with a prior report [29],
we found that GCase co-immunoprecipitated with
progranulin (Fig. 6a).
We next performed in situ analysis of progranulin
and GCase interaction by proximity ligation assay
(PLA). HEK-293 cells were transfected with HA-GRN
and GBA-myc-Flag constructs and processed for PLA
48 h later. We detected abundant PLA signal in cells
transfected with both constructs and probed with HA
and Flag antibodies (Fig. 6b). We detected essentially
no PLA signal in negative control cells transfected
with only one of the constructs, or when omitting the
primary antibodies on cells transfected with both con-
structs (Fig. 6c).
Fig. 4 Loss of Neuronal GCase in FTD-GRN. a, GCase immunostained sections were counterstained with hematoxylin to identify neurons, which
revealed both fewer neurons (t test, p = 0.0437) and less neuronal area (b, t test, p = 0.0458) in layer III of FTD-GRN patients than controls, consistent
with neurodegeneration. c, Within these hematoxylin-labeled neurons, FTD-GRN patients had less GCase immunolabeling than controls (t test, p =
0.031). This observation survived correction for the lower total neuronal area (d, t test, p = 0.048), indicating that the reduced GCase in FTD-GRN brains
is unlikely to be explained solely by neuronal loss. n = 5 controls and 7 FTD-GRN patients. e, The intensity of fluorescent GCase immunolabeling in
cortical neurons was also reduced in FTD-GRN patients, with quantification of neuronal GCase intensity shown in f, cumulative probability plots and g,
density plots. These data were analyzed first by Kolmogorov-Smirnov test, showing significantly lower neuronal GCase in FTD-GRN (p < 0.0001). A more
conservative mixed-model regression of the fluorescent intensity distribution data confirmed that the distribution of FTD-GRN neurons was skewed
toward less intense labeling than controls, with significant group differences found in the 60th (p = 0.007), 70th (p = 0.001), 80th (p = 0.005) and 90th
(p = 0.022) deciles. n = 519 neurons from 5 controls and 262 neurons from 6 FTD-GRN patients. All images are labeled with the corresponding case
number from Table 1. Representative 40X images of GCase and NeuN immunostaining are shown in e with a 20 μm scale bar
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GCase activity deficits in Grn−/− mice
To assess the effects of progranulin insufficiency on GCase
activity independent of neurodegeneration in an experimen-
tally manipulable model, we measured activity of GCase and
other sphingolipid-metabolizing enzymes in frontal cortical
lysates from 7 to 10-month-old progranulin-insufficient
mice. Except for GCase, Grn−/− mice had elevated activity of
every enzyme measured (β-Gal, β-Hex (total), HexA, and
GLA, Fig. 7b–e). Similar to FTD-GRN patients, Grn−/− mice
had reduced GCase activity (Fig. 7f). We did not observe
any significant changes in enzyme activity in Grn+/− mice,
although we previously observed that older Grn+/− mice
(12–20months) exhibit elevated HexA and GCase activity
[3]. These data indicate that progranulin insufficiency
impairs cortical GCase activity in the absence of neuronal
loss and indicate that GCase requires progranulin for nor-
mal activity in the brain.
Progranulin gene therapy normalizes GCase activity in
Grn−/− mice
Since progranulin insufficiency impairs GCase activity in
the brain, we hypothesized that restoration of progranu-
lin would normalize GCase activity. We have previously
shown that AAV-mediated restoration of progranulin to
Grn−/− mice reduces lipofuscinosis and normalizes ele-
vated cathepsin D activity [4]. We therefore analyzed
GCase activity in tissue samples from the mice in our
previous study [4] to determine if restoration of progra-
nulin could normalize GCase deficits. These mice were
treated with AAV-progranulin (AAV-Grn) or AAV-GFP
by infusion into the medial prefrontal cortex at 10–12
months of age and euthanized 8–10 weeks later for brain
collection. We began our investigation of GCase activity
with ventral striatum lysates in which we previously ob-
served normalization of cathepsin D activity [4]. We ob-
served a genotype-specific effect of AAV-Grn. AAV-Grn
boosted GCase activity in Grn−/− mice (Fig. 7g), showing
that restoration of progranulin can improve GCase defi-
cits. In contrast, AAV-Grn suppressed GCase activity in
wild-type mice. This was somewhat surprising but con-
sistent with our prior observations of reduced cathepsin
D activity in AAV-Grn-treated wild-type mice [4].
To confirm this finding, we analyzed tissue samples
from a second group of mice treated with AAV-Grn by
infusion into the medial prefrontal cortex at 3–6 months
of age and euthanized for analysis 4 weeks later (average
age at euthanasia = 5.9 months). Similar to the first co-
hort, we found that restoration of progranulin with
AAV-Grn gene therapy in Grn−/− mice normalized
GCase deficits across multiple brain regions (Fig. 7h).
Discussion
This study shows that progranulin insufficiency impairs
GCase activity in the frontal cortex of patients with FTD-
GRN. GCase was the only sphingolipid-metabolizing
enzyme among those analyzed in this study to show
impaired activity in FTD-GRN patients, suggesting a spe-
cific GCase deficit, rather than a general deficit in
sphingolipid metabolism. We found evidence in FTD-
GRN patients for abnormal GCase processing, with
Fig. 5 Brains from FTD-GRN Patients Do Not Accumulate Glucosylceramide or Glucosylsphingosine. Lipids were extracted from lysates of inferior
frontal gyrus of control and FTD-GRN patients and analyzed by high performance liquid chromatography/mass spectrometry. No group
differences were detected in glucosylceramide isoforms (a, MANOVA effect of group, p = 0.954), total levels of glucosylceramide (b, t test, p =
0.8470), or glucosylsphingosine (c, t test, p = 0.4199). n = 5 controls and 5 FTD-GRN. GlcCer = glucosylceramide, GlcSph = glucosylsphingosine
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incomplete glycosylation and accumulation in the
sarkosyl-insoluble fraction. GCase impairment in FTD-
GRN patients is likely the direct result of progranulin in-
sufficiency, as Grn−/− mice also exhibited impaired GCase
activity that was normalized by restoring progranulin with
AAV-Grn gene therapy.
Brains from FTD-GRN patients accumulate lysosomal
proteins, possibly due to underlying lysosomal dysfunc-
tion [25], and this study indicates that GCase deficits
may be a component of the underlying lysosomal dys-
function. These GCase deficits may be caused by im-
paired GCase processing due to progranulin
insufficiency. This work adds to prior reports that pro-
granulin interacts with GCase [29, 30], and recent re-
ports of reduced GCase activity in brains from Grn−/−
mice [72] and iPSC-derived neurons from GRN muta-
tion carriers [65], further supporting the requirement of
progranulin for normal GCase activity in the brain.
Regulation of lysosomal enzyme activity may be a key
function of progranulin. Progranulin also regulates the
activity of cathepsin D [6, 11, 12, 64, 71] and HexA [14].
For both cathepsin D and HexA, we and others have
observed potentially compensatory increases in expres-
sion in FTD-GRN patients [25] and progranulin-
insufficient mice [3, 24, 25, 33, 61, 62] that stands in
contrast to the GCase deficits reported in the present
study. Interestingly, we also observed increased GCase
activity in a prior study of Grn+/− mice [3]. This contrast
may be explained by a GCase processing deficit that
emerges when progranulin levels fall below a certain
threshold. Progranulin-insufficient cells may compen-
sate for impaired HexA and CatD activity by increasing
HexA and CatD expression, but may be unable to compen-
sate for impaired GCase activity due to impaired GCase
processing.
The role of impaired GCase activity in FTD-GRN
pathogenesis will be an important topic for future inves-
tigation. It is notable that the clinical spectrum of pa-
tients with GRN mutations is quite different from that of
patients with GBA mutations. Homozygous GRN muta-
tion carriers develop the lysosomal storage disorder
NCL [2, 31, 59], and heterozygous carriers typically de-
velop dominantly inherited FTD [5, 16], though some
develop other disorders such as Alzheimer’s disease,
Fig. 6 Progranulin Interacts with GCase. HEK-293 cells were co-transfected with constructs expressing HA-tagged human progranulin and/or myc-flag-
tagged human GCase. HA-tagged progranulin was then immunoprecipitated from cell lysates with an anti-HA antibody. a, Flag-tagged GCase co-
immunoprecipitated with progranulin, indicating interaction of the two proteins. b, Consistent with the co-immunoprecipitation of GCase with
progranulin, we detected strong proximity ligation (PLA) signal in HEK-293 cells co-transfected with human progranulin and human GCase constructs.
c, The specificity of the Flag-HA PLA signal was confirmed by the presence of significantly more PLA puncta from cells co-transfected with the
progranulin-HA and GCase-Flag constructs than in cells transfected with only one of the constructs, or from cells that underwent PLA in the absence
of the HA and Flag antibodies (ANOVA effect of experimental condition, p < 0.0001, *** = p < 0.001 and **** = p < 0.0001 by Dunnett’s post-hoc test).
The scale bars represents 5 μm. GCase = β-glucocerebrosidase, GRN = progranulin, PLA = proximity ligation assay
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Parkinson’s disease (PD), or DLB [10, 32, 56, 68]. In con-
trast, homozygous GBA mutation carriers develop the
lysosomal storage disorder Gaucher disease [26], and
heterozygous carriers are at increased risk for PD and
DLB [1, 42, 48]. PD and DLB patients without GBA mu-
tations also exhibit GCase activity deficits in certain
brain regions [15, 21, 39, 55], perhaps due to impairment
of GCase activity by α-synuclein [38]. Available data in-
dicate that GBA mutations do not increase risk for AD
[63]. There is even less data on the influence of GBA
mutations on FTD. One study reported increased inci-
dence of GBA mutations in patients with corticobasal
syndrome, but not other FTD subtypes [51]. Based on
available data on progranulin’s role in the lysosome, it
seems possible that GCase deficits are one of several
lysosomal deficits in GRN mutation carriers that contrib-
ute to disease. Defining progranulin’s lysosomal interac-
tome and the lysosomal deficits induced by progranulin
insufficiency may help clarify the role of GCase deficits
in FTD-GRN pathogenesis.
GBA mutations are a major risk factor for PD and
DLB [1, 42, 48], so the impairment of GCase activity in
FTD-GRN patients and Grn−/− mice raises the question
of whether GRN mutations or variants may also in-
crease PD and DLB risk. GRN mutation carriers occa-
sionally develop PD or DLB [10, 32, 56, 68], though
they usually develop an FTD syndrome with TDP-43
pathology. Genetic studies testing for association of
GRN variants with PD have produced mixed results
[13, 28, 34, 47], though a preprint report of a large
genome-wide association study has identified GRN as a
risk gene for PD [41]. Interestingly, PD patients have
lower circulating progranulin levels than controls [34].
Gaucher disease patients also have lower levels of
serum progranulin than controls and have higher fre-
quencies of GRN gene variants associated with lower
progranulin levels [30]. In mouse models, progranulin
is protective against dopaminergic neuronal loss due to
MPTP [37, 66]. This protection has been associated
with progranulin’s anti-inflammatory effects. However,
Fig. 7 Grn−/− Mice Have GCase Activity Deficits That Are Corrected by Restoration of Progranulin with an AAV Vector. Frontal cortical lysates from
7 to 10 month-old wild-type, Grn+/−, and Grn
−/− littermates were analyzed for activity of GSL-metabolizing enzymes. A simplified diagram of
ganglioside metabolism, with a summary of observed phenotypes in Grn−/− mice is shown in a. Lipids are shown in black, with the enzymes that
metabolize each lipid shown in blue. GM1, 2, and 3 = GM1, 2, and 3 ganglioside, β-Gal = β-galactosidase, β-Hex = β-Hexosaminidase, HexA = β-
Hexosaminidase A, GLA = α-galactosidase A, GCase = β-glucocerebrosidase, Neu = neuraminidase (activity not measured in this study). b–f, At this
age, Grn−/− mice exhibited significant increases in activity of β-Gal (b, ANOVA, p = 0.0024), β-Hex (c, ANOVA, p < 0.0001), HexA (d, ANOVA, p <
0.0001), and GLA (e, ANOVA, p < 0.0001). However, Grn−/− mice exhibited a decrease in GCase activity (f, ANOVA, p = 0.0099). n = 6–24 per
genotype. * = p < 0.05 ** = p < 0.1, **** = p < 0.0001 by Dunnett’s post-hoc test. g, Analysis of ventral striatum samples from a cohort of Grn−/−
mice treated with AAV-GFP or AAV-progranulin in the medial prefrontal cortex revealed that restoring progranulin to Grn−/− mice normalized
GCase deficits (ANOVA genotype x treatment interaction, p = 0.0122), but that AAV-Grn reduced GCase activity in wild-type mice. h, Analysis of
multiple brain regions from a second group of AAV-treated mice produced similar results, (RM ANOVA, genotype x virus x brain region, p =
0.042). Subsequent tests of the effects of virus within genotype confirmed the opposite effects of AAV-Grn in each genotype. In wild-type mice,
AAV-Grn reduced GCase activity (RM ANOVA effect of virus, p = 0.0088), but in Grn−/− mice, AAV-Grn increased GCase activity to near wild-type
levels (RM ANOVA effect of virus, p = 0.0072). * = p < 0.05 and **** = p < 0.0001 by Sidak’s post-hoc test. n = 8–11 mice per group in g, with 4
uninjected Grn−/− mice included as a reference, and 4–6 mice per group in h. β-Gal = β-galactosidase, β-Hex = β-Hexosaminidase, HexA = β-
Hexosaminidase A, GLA = α-galactosidase A, GCase = β-glucocerebrosidase, Neu = neuraminidase (activity not measured in this study)
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it is possible that progranulin’s interaction with GCase
could play a role, as both Grn−/− mice and Gba+/L444P
mice are more sensitive than wild-type mice to MPTP-
induced dopaminergic neuronal loss [37, 70]. Thus,
while current data on a role for progranulin in PD or
DLB are sparse, this may be an interesting topic for
future study.
The GCase deficits in Grn−/− mice show that progranulin
insufficiency alone modestly impairs GCase activity in the
brain, but we also obtained evidence that disease state may
influence GCase activity in GRN mutation carriers. It is
quite rare for a GRN mutation carrier to come to autopsy
before developing FTD, as we observed in one case (#7 in
Table 1). In this case, which had only the beginnings of
FTLD-TDP type A pathology (Additional file 3: Figure S3f),
we did not observe the GCase abnormalities that were
present in GRN cases with FTD-spectrum disorders and
FTLD-TDP type A pathology: GCase activity (Additional file
3: Figure S3c) and GCase protein levels (Additional file 3:
Figure S3d,e) were within the range of controls, and the low
molecular weight GCase band was not observed in either
soluble or insoluble fractions (Additional file 3: Figure S3a,
b). Interestingly, this patient had a synucleinopathy, with a
DLB clinical syndrome and Lewy body disease pathology
(Table 1). Synucleinopathies including PD and DLB have
been associated with GCase abnormalities, particularly in
the substantia nigra [15, 21, 39, 55], so one might have ex-
pected to see GCase abnormalities even in the absence of
significant FTD or FTLD pathology. However, patients with
PD and DLB do not typically exhibit GCase deficits in the
frontal cortex [15, 21, 39, 55]. Thus, the lack of GCase defi-
cits in this case are consistent with data on patients with
DLB. Although it is a single case, if confirmed in future
studies, these observations would suggest that the GCase ab-
normalities we observed correlate with onset of dysfunction.
Conclusions
In summary, these data expand our knowledge of the
lysosomal dysfunction induced by progranulin insuffi-
ciency in the brain. We have shown that progranulin in-
sufficiency impairs GCase activity in the brain, likely by
disrupting GCase processing, and that restoration of
progranulin corrects these activity deficits in Grn−/−
mice. Future studies will investigate the role of these
GCase deficits in FTD pathogenesis.
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